亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Phase I/II Study of Concurrent Chemoradiotherapy for Localized Nasal Natural Killer/T-Cell Lymphoma: Japan Clinical Oncology Group Study JCOG0211

医学 依托泊苷 粘膜炎 异环磷酰胺 内科学 卡铂 放化疗 放射治疗 胃肠病学 中性粒细胞减少症 临床研究阶段 淋巴瘤 外科 化疗 肿瘤科 顺铂
作者
Motoko Yamaguchi,Kensei Tobinai,Masahiko Oguchi,Naoki Ishizuka,Yukio Kobayashi,Yasushi Isobe,Kenichi Ishizawa,Nobuo Maseki,Kuniaki Itoh,Noriko Usui,Izumi Wasada,Tomohiro Kinoshita,Koichi Ohshima,Yoshihiro Matsuno,Takashi Terauchi,Shigeru Nawano,Satoshi Ishikura,Yoshikazu Kagami,Tomomitsu Hotta,Kazuo Oshimi
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:27 (33): 5594-5600 被引量:334
标识
DOI:10.1200/jco.2009.23.8295
摘要

Purpose To explore a more effective treatment for localized nasal natural killer (NK)/T-cell lymphoma, we conducted a phase I/II study of concurrent chemoradiotherapy. Patients and Methods Treatments comprised concurrent radiotherapy (50 Gy) and 3 courses of dexamethasone, etoposide, ifosfamide, and carboplatin (DeVIC). Patients with a newly diagnosed stage IE or contiguous IIE disease with cervical node involvement and a performance status (PS) of 0 to 2 were eligible for enrollment. The primary end point of the phase II portion was a 2-year overall survival in patients treated with the recommended dose. Results Of the 33 patients enrolled, 10 patients were enrolled in the phase I portion and a two thirds dose of DeVIC was established as the recommended dose. Twenty-seven patients (range, 21 to 68; median, 56 years) treated with the recommended dose showed the following clinical features: male:female, 17:10; stage IE, 18; stage IIE, 9; B symptoms present, 10; elevated serum lactate dehydrogenase, 5; and PS 2, 2. With a median follow-up of 32 months, the 2-year overall survival was 78% (95% CI, 57% to 89%). This compared favorably with the historical control of radiotherapy alone (45%). Of the 26 patients assessable for a response, 20 (77%) achieved a complete response, with one partial response. The overall response rate was 81%. The most common grade 3 nonhematologic toxicity was mucositis related to radiation (30%). No treatment-related deaths were observed. Conclusion Concurrent chemoradiotherapy using multidrug resistance-nonrelated agents and etoposide is a safe and effective treatment for localized nasal NK/T-cell lymphoma and warrants further investigation.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
null的应助被Younger采纳,获得10
刚刚
刚刚
anniver732发布了新的文献求助10
刚刚
刚刚
anniver732发布了新的文献求助10
1秒前
anniver732发布了新的文献求助10
1秒前
anniver732发布了新的文献求助20
1秒前
anniver732发布了新的文献求助10
1秒前
anniver732发布了新的文献求助20
2秒前
3秒前
anniver732发布了新的文献求助10
4秒前
anniver732发布了新的文献求助10
4秒前
anniver732发布了新的文献求助10
4秒前
4秒前
anniver732发布了新的文献求助10
4秒前
anniver732发布了新的文献求助10
5秒前
5秒前
漂亮孤风完成签到,获得积分10
5秒前
anniver732发布了新的文献求助10
5秒前
anniver732发布了新的文献求助10
5秒前
5秒前
6秒前
7秒前
7秒前
anniver732发布了新的文献求助10
8秒前
anniver732发布了新的文献求助10
8秒前
anniver732发布了新的文献求助10
8秒前
anniver732发布了新的文献求助10
8秒前
anniver732发布了新的文献求助10
8秒前
8秒前
null的应助被Younger采纳,获得10
9秒前
科研通AI6.2的应助被甜甜的悲采纳,获得10
9秒前
10秒前
赘婿的应助被难过的鸡翅采纳,获得10
10秒前
11秒前
11秒前
叶子完成签到 ,获得积分10
11秒前
anniver732发布了新的文献求助20
11秒前
anniver732发布了新的文献求助10
11秒前
anniver732发布了新的文献求助10
12秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Hidden Empire of Finance: How Wall Street Profits from Our Cities and Fuels Global Inequality 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8165968
求助须知:如何正确求助?哪些是违规求助? 9559396
关于积分的说明 21749984
捐赠科研通 7756746
什么是DOI,文献DOI怎么找? 3429092
关于科研通互助平台的介绍 2553386
邀请新用户注册赠送积分活动 2473667